1609 related articles for article (PubMed ID: 15023890)
1. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure.
Cataliotti A; Boerrigter G; Costello-Boerrigter LC; Schirger JA; Tsuruda T; Heublein DM; Chen HH; Malatino LS; Burnett JC
Circulation; 2004 Apr; 109(13):1680-5. PubMed ID: 15023890
[TBL] [Abstract][Full Text] [Related]
2. Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure.
Rademaker MT; Charles CJ; Nicholls MG; Richards AM
Circ Heart Fail; 2009 Nov; 2(6):532-40. PubMed ID: 19919977
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure.
Chen HH; Redfield MM; Nordstrom LJ; Cataliotti A; Burnett JC
Am J Physiol Renal Physiol; 2003 May; 284(5):F1115-9. PubMed ID: 12676739
[TBL] [Abstract][Full Text] [Related]
4. Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study.
Paterna S; Di Pasquale P; Parrinello G; Fornaciari E; Di Gaudio F; Fasullo S; Giammanco M; Sarullo FM; Licata G
J Am Coll Cardiol; 2005 Jun; 45(12):1997-2003. PubMed ID: 15963399
[TBL] [Abstract][Full Text] [Related]
5. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine.
Wang DJ; Dowling TC; Meadows D; Ayala T; Marshall J; Minshall S; Greenberg N; Thattassery E; Fisher ML; Rao K; Gottlieb SS
Circulation; 2004 Sep; 110(12):1620-5. PubMed ID: 15337695
[TBL] [Abstract][Full Text] [Related]
6. TRV120027, a novel β-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure.
Boerrigter G; Soergel DG; Violin JD; Lark MW; Burnett JC
Circ Heart Fail; 2012 Sep; 5(5):627-34. PubMed ID: 22891045
[TBL] [Abstract][Full Text] [Related]
7. Increased urinary aquaporin-2 excretion in response to furosemide in patients with chronic heart failure.
Starklint J; Bech JN; Nyvad O; Jensen P; Pedersen EB
Scand J Clin Lab Invest; 2006; 66(1):55-66. PubMed ID: 16464787
[TBL] [Abstract][Full Text] [Related]
8. Low-dose atrial natriuretic factor and furosemide in experimental acute congestive heart failure.
Fett DL; Cavero PG; Burnett JC
J Am Soc Nephrol; 1993 Aug; 4(2):162-7. PubMed ID: 8400079
[TBL] [Abstract][Full Text] [Related]
9. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.
Licata G; Di Pasquale P; Parrinello G; Cardinale A; Scandurra A; Follone G; Argano C; Tuttolomondo A; Paterna S
Am Heart J; 2003 Mar; 145(3):459-66. PubMed ID: 12660669
[TBL] [Abstract][Full Text] [Related]
10. Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure.
Costello-Boerrigter LC; Boerrigter G; Cataliotti A; Harty GJ; Burnett JC
Circ Heart Fail; 2010 May; 3(3):412-9. PubMed ID: 20176717
[TBL] [Abstract][Full Text] [Related]
11. Renal effects of brain natriuretic peptide in patients with congestive heart failure.
Jensen KT; Eiskjaer H; Carstens J; Pedersen EB
Clin Sci (Lond); 1999 Jan; 96(1):5-15. PubMed ID: 9857101
[TBL] [Abstract][Full Text] [Related]
12. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y
Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782
[TBL] [Abstract][Full Text] [Related]
13. Medium term effects of different dosage of diuretic, sodium, and fluid administration on neurohormonal and clinical outcome in patients with recently compensated heart failure.
Paterna S; Parrinello G; Cannizzaro S; Fasullo S; Torres D; Sarullo FM; Di Pasquale P
Am J Cardiol; 2009 Jan; 103(1):93-102. PubMed ID: 19101237
[TBL] [Abstract][Full Text] [Related]
14. Chronic administration of phosphodiesterase type 5 inhibitor suppresses renal production of endothelin-1 in dogs with congestive heart failure.
Yamamoto T; Wada A; Ohnishi M; Tsutamoto T; Fujii M; Matsumoto T; Takayama T; Wang X; Kurokawa K; Kinoshita M
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():258S-262S. PubMed ID: 12193099
[TBL] [Abstract][Full Text] [Related]
15. Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition.
Chen HH; Lainchbury JG; Harty GJ; Burnett JC
Circulation; 2002 Feb; 105(8):999-1003. PubMed ID: 11864932
[TBL] [Abstract][Full Text] [Related]
16. Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure.
Chen HH; Huntley BK; Schirger JA; Cataliotti A; Burnett JC
J Am Soc Nephrol; 2006 Oct; 17(10):2742-7. PubMed ID: 16928803
[TBL] [Abstract][Full Text] [Related]
17. Activation of myocardial and renal natriuretic peptides during acute intravascular volume overload in dogs: functional cardiorenal responses to receptor antagonism.
Borgeson DD; Stevens TL; Heublein DM; Matsuda Y; Burnett JC
Clin Sci (Lond); 1998 Aug; 95(2):195-202. PubMed ID: 9680502
[TBL] [Abstract][Full Text] [Related]
18. Administration of brain natriuretic peptide improves cardiac function following operations using extracorporeal circulation in an animal model.
Bail DH; Steger V; Heinzelmann U; Schiller S; Geim AI; Brüllmann B; Ziemer G
Clin Sci (Lond); 2007 Mar; 112(5):315-24. PubMed ID: 17073825
[TBL] [Abstract][Full Text] [Related]
19. Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritide.
Kurien S; Warfield KT; Wood CM; Miller WL
Am J Cardiol; 2006 Dec; 98(12):1627-30. PubMed ID: 17145223
[TBL] [Abstract][Full Text] [Related]
20. Biological actions of brain natriuretic peptide in thoracic inferior vena caval constriction.
Clavell AL; Stingo AJ; Aarhus LL; Burnett JC
Am J Physiol; 1993 Dec; 265(6 Pt 2):R1416-22. PubMed ID: 8285286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
